ArticleJournal of applied clinical medical physics2026
Explainable machine learning for patient-specific quality assurance in intensity-modulated radiotherapy based on anatomical structures.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPatient-specific quality assurance (PSQA) plays a pivotal role in intensity-modulated radiotherapy (IMRT) to ensure accurate dose delivery. However, conventional measurement-based PSQA approaches are labor-intensive and provide limited insight into the underlying factors contributing to variations in gamma passing rates (GPRs). Anatomical characteristics of the planning target volume (PTV) and organs at risk (OARs) may contain predictive information relevant to GPR performance, yet their potential has not been fully explored within interpretable machine learning frameworks. PURPOSE: This study aimed to develop an interpretable machine learning (ML) framework for predicting GPRs in IMRT based on anatomical features extracted from the PTV and OARs.
methodsA retrospective cohort of 243 clinical chest IMRT plans was analyzed. Radiomic and dosimetric features were extracted for each anatomical structure. Two ML regression models-Random Forest (RF) and eXtreme Gradient Boosting (XGBoost)-were developed to predict GPRs for the PTV and OARs under four gamma criteria (3%/3 mm, 3%/2 mm, 2%/3 mm, and 2%/2 mm). The GPR obtained by comparing the dose distribution reconstructed using the independent Monte Carlo (MC) dose calculation software ArcherQA (Wisdom Technology Company Limited, Hefei, China)-based on linear accelerator delivery log files-with the original planned dose distribution was used as the reference standard, and calculated using global gamma analysis with a 10% dose threshold. Model performance was evaluated using the mean absolute error (MAE), root mean square error (RMSE), and Spearman's rank correlation coefficient. Shapley Additive Explanations (SHAP) were applied to interpret feature contributions in the best-performing model.
resultsBoth models demonstrated robust predictive performance across different anatomical structures and gamma criteria. As the gamma criteria became less stringent, prediction errors decreased accordingly. Prediction accuracy was relatively high for OARs; for example, under the 3%/3 mm criterion, the test-set MAE was 0.06% ± 0.01% for the heart and 0.26% ± 0.04% for the whole lung. In contrast, the prediction error was relatively larger for the PTV, with a test-set MAE of 1.98% ± 0.31% under the same criterion. SHAP analysis revealed that texture-related radiomic features contributed most substantially to model predictions. Moreover, feature importance patterns varied according to organ type and gamma-criterion stringency.
conclusionsMulti-omics descriptors derived from anatomical structures can reliably predict GPRs in IMRT. The proposed interpretable ML framework not only achieves accurate prediction but also enhances mechanistic understanding through SHAP-based explanations. These findings provide valuable insights into dose verification variability and offer a practical, transparent tool for IMRT patient-specific quality assurance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.